Histogenics Corp. (NASDAQ:HSGX)’s share price traded down 8.7% during trading on Wednesday . The company traded as low as $2.84 and last traded at $3.37, with a volume of 232,524 shares traded. The stock had previously closed at $3.69.

A number of equities analysts have commented on the stock. Canaccord Genuity reaffirmed a “buy” rating on shares of Histogenics Corp. in a research report on Thursday, May 12th. BTIG Research raised shares of Histogenics Corp. from a “neutral” rating to a “buy” rating and set a $3.50 price objective for the company in a research report on Thursday, August 11th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Histogenics Corp. currently has a consensus rating of “Buy” and an average price target of $9.75.

The stock’s market capitalization is $42.20 million. The firm has a 50 day moving average price of $2.07 and a 200-day moving average price of $2.20.

Histogenics Corp. (NASDAQ:HSGX) last posted its quarterly earnings results on Thursday, August 11th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.01. During the same period last year, the company posted ($0.58) earnings per share. On average, analysts forecast that Histogenics Corp. will post ($2.09) EPS for the current fiscal year.

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.